Latest Videos |view all videos
Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology.
Mayo Clinic Researchers Help to Shine New Light on Bladder Cancer Tumors.
Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease
Charanjit S. Rihal, M.D., and Stephen L. Kopecky, M.D., discuss erectile dysfunction and its impact on cardiovascular prognosis and diagnosis.
The Prostate Cancer Medically Optimized Genome Enhanced Therapy Study (PROMOTE) aims to individualize treatments for men with castration-resistant prostate cancer.
Robert D. Simari, MD, and Rajiv Gulati, MD, PhD discuss the data so far and the ongoing Symplicity-HTN3 trial. Will renal denervation move hypertension into the interventional cardiologists' domain?
Eddie Greene, MD, Horng Chen, MB, BCh, and Margaret Redfield, MD, gathered to discuss the design, results, and implications of the cardiorenal rescue study in acute decompensated heart failure (CARRESS).
Mayo Clinic has integrated production, imaging and pathology facilities to provide the benefit of Choline C 11 PET imaging to prostate cancer patients.
Dr. Manish Kohli of Mayo Clinic discusses his January 2010 Mayo Clinic Proceedings article on new developments in the medical management of prostate cancer.